SpecificiT's Seed VC Round

SpecificiT raised a round of funding on September 11, 2017.

SpecificiT is developing cellular therapies for hematological cancers, which cannot be treated with Chimeric Receptor Antigen of T cells.…

Articles about SpecificiT's Seed VC Round: